Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Southern Asia has been increasing steadily in recent years.
Customer preferences: Patients suffering from rheumatic diseases in Southern Asia are increasingly opting for Anti-Rheumatic Drugs due to their effectiveness in reducing inflammation and managing pain. The preference for these drugs is also driven by the increasing awareness about rheumatic diseases and the availability of affordable treatment options.
Trends in the market: India is the largest market for Anti-Rheumatic Drugs in Southern Asia, accounting for a significant share of the overall demand. The market is expected to grow further due to the increasing prevalence of rheumatic diseases and the rising geriatric population. In addition, the availability of low-cost generic drugs is also driving the demand for Anti-Rheumatic Drugs in the region.
Local special circumstances: In Southern Asia, the prevalence of rheumatic diseases is higher among women, which is driving the demand for Anti-Rheumatic Drugs among this demographic. In addition, the lack of awareness about rheumatic diseases and the stigma associated with such diseases is a major challenge in the region. Governments and healthcare organizations are working to increase awareness and improve access to treatment options.
Underlying macroeconomic factors: The economic growth in Southern Asia has led to an increase in healthcare spending, which is driving the growth of the Anti-Rheumatic Drugs market in the region. In addition, the increasing prevalence of rheumatic diseases and the rising geriatric population are expected to drive the demand for Anti-Rheumatic Drugs in the region in the coming years. However, the lack of healthcare infrastructure and the limited availability of healthcare professionals in some parts of the region are challenges that need to be addressed.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
